Walgreens Boots Alliance, Inc. (0LSZ.L)
USD 10.79
(-2.13%)
USD 10.79
(-2.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 | 68.85 Billion USD | 1.06% |
| 2023 | 68.13 Billion USD | 14.1% |
| 2022 | 59.71 Billion USD | 3.92% |
| 2021 | 57.46 Billion USD | -12.98% |
| 2020 | 66.03 Billion USD | 52.0% |
| 2019 | 43.44 Billion USD | 4.85% |
| 2018 | 41.43 Billion USD | 9.81% |
| 2017 | 37.73 Billion USD | -11.02% |
| 2016 | 42.4 Billion USD | 13.14% |
| 2015 | 37.48 Billion USD | 125.51% |
| 2014 | 16.62 Billion USD | 3.71% |
| 2013 | 16.02 Billion USD | 5.26% |
| 2012 | 15.22 Billion USD | 20.77% |
| 2011 | 12.6 Billion USD | 6.16% |
| 2010 | 11.87 Billion USD | 10.3% |
| 2009 | 10.76 Billion USD | 12.84% |
| 2008 | 9.54 Billion USD | 16.22% |
| 2007 | 8.2 Billion USD | 17.02% |
| 2006 | 7.01 Billion USD | 22.66% |
| 2005 | 5.71 Billion USD | 11.83% |
| 2004 | 5.11 Billion USD | 21.47% |
| 2003 | 4.21 Billion USD | 15.39% |
| 2002 | 3.64 Billion USD | 0.61% |
| 2001 | 3.62 Billion USD | 26.38% |
| 2000 | 2.86 Billion USD | 18.47% |
| 1999 | 2.42 Billion USD | 17.99% |
| 1998 | 2.05 Billion USD | 11.94% |
| 1997 | 1.83 Billion USD | 15.31% |
| 1996 | 1.59 Billion USD | 8.94% |
| 1995 | 1.46 Billion USD | 9.36% |
| 1994 | 1.33 Billion USD | 15.45% |
| 1993 | 1.15 Billion USD | 1.41% |
| 1992 | 1.14 Billion USD | 12.52% |
| 1991 | 1.01 Billion USD | 4.87% |
| 1990 | 966.3 Million USD | 12.66% |
| 1989 | 857.7 Million USD | 7.31% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 67.55 Billion USD | -1.87% |
| 2024 Q1 | 70.06 Billion USD | 2.83% |
| 2024 Q4 | 68.85 Billion USD | 1.93% |
| 2024 Q2 | 68.84 Billion USD | -1.75% |
| 2023 Q2 | 70.88 Billion USD | 4.03% |
| 2023 FY | 68.13 Billion USD | 14.1% |
| 2023 Q1 | 68.13 Billion USD | 14.1% |
| 2023 Q3 | 69.08 Billion USD | -2.53% |
| 2023 Q4 | 68.13 Billion USD | -1.37% |
| 2022 FY | 59.71 Billion USD | 3.92% |
| 2022 Q4 | 59.71 Billion USD | -3.06% |
| 2022 Q2 | 61.81 Billion USD | -6.24% |
| 2022 Q1 | 65.92 Billion USD | 14.73% |
| 2022 Q3 | 61.6 Billion USD | -0.34% |
| 2021 Q3 | 69.32 Billion USD | 0.04% |
| 2021 Q4 | 57.46 Billion USD | -17.11% |
| 2021 Q1 | 68.6 Billion USD | 3.89% |
| 2021 Q2 | 69.29 Billion USD | 1.01% |
| 2021 FY | 57.46 Billion USD | -12.98% |
| 2020 FY | 66.03 Billion USD | 52.0% |
| 2020 Q1 | 66.49 Billion USD | 53.05% |
| 2020 Q2 | 65.66 Billion USD | -1.24% |
| 2020 Q3 | 65.12 Billion USD | -0.83% |
| 2020 Q4 | 66.03 Billion USD | 1.41% |
| 2019 FY | 43.44 Billion USD | 4.85% |
| 2019 Q3 | 43.81 Billion USD | -2.68% |
| 2019 Q4 | 43.44 Billion USD | -0.84% |
| 2019 Q2 | 45.02 Billion USD | 3.07% |
| 2019 Q1 | 43.67 Billion USD | 5.41% |
| 2018 FY | 41.43 Billion USD | 9.81% |
| 2018 Q1 | 39.86 Billion USD | 5.64% |
| 2018 Q2 | 42.63 Billion USD | 6.96% |
| 2018 Q3 | 41.68 Billion USD | -2.24% |
| 2018 Q4 | 41.43 Billion USD | -0.59% |
| 2017 Q1 | 42.22 Billion USD | -0.44% |
| 2017 FY | 37.73 Billion USD | -11.02% |
| 2017 Q4 | 37.73 Billion USD | -11.6% |
| 2017 Q3 | 42.68 Billion USD | 1.44% |
| 2017 Q2 | 42.08 Billion USD | -0.32% |
| 2016 Q3 | 36.01 Billion USD | -1.23% |
| 2016 Q2 | 36.46 Billion USD | -2.76% |
| 2016 FY | 42.4 Billion USD | 13.14% |
| 2016 Q4 | 42.4 Billion USD | 17.74% |
| 2016 Q1 | 37.5 Billion USD | 0.06% |
| 2015 Q4 | 37.48 Billion USD | -3.18% |
| 2015 Q2 | 40.33 Billion USD | 44.84% |
| 2015 Q1 | 27.84 Billion USD | 67.53% |
| 2015 FY | 37.48 Billion USD | 125.51% |
| 2015 Q3 | 38.71 Billion USD | -4.01% |
| 2014 Q1 | 16.42 Billion USD | 2.48% |
| 2014 Q4 | 16.62 Billion USD | 4.5% |
| 2014 Q3 | 15.9 Billion USD | -2.1% |
| 2014 Q2 | 16.24 Billion USD | -1.08% |
| 2014 FY | 16.62 Billion USD | 3.71% |
| 2013 FY | 16.02 Billion USD | 5.26% |
| 2013 Q4 | 16.02 Billion USD | -4.95% |
| 2013 Q3 | 16.86 Billion USD | 1.63% |
| 2013 Q2 | 16.59 Billion USD | -1.71% |
| 2013 Q1 | 16.88 Billion USD | 10.86% |
| 2012 Q1 | 12.75 Billion USD | 1.17% |
| 2012 FY | 15.22 Billion USD | 20.77% |
| 2012 Q4 | 15.22 Billion USD | 25.22% |
| 2012 Q3 | 12.15 Billion USD | 2.99% |
| 2012 Q2 | 11.8 Billion USD | -7.44% |
| 2011 Q3 | 12.59 Billion USD | 3.25% |
| 2011 Q4 | 12.6 Billion USD | 0.11% |
| 2011 Q1 | 12.68 Billion USD | 6.79% |
| 2011 Q2 | 12.19 Billion USD | -3.82% |
| 2011 FY | 12.6 Billion USD | 6.16% |
| 2010 Q2 | 11.38 Billion USD | -4.54% |
| 2010 FY | 11.87 Billion USD | 10.3% |
| 2010 Q1 | 11.92 Billion USD | 10.78% |
| 2010 Q4 | 11.87 Billion USD | 2.41% |
| 2010 Q3 | 11.59 Billion USD | 1.84% |
| 2009 Q4 | 10.76 Billion USD | -1.73% |
| 2009 FY | 10.76 Billion USD | 12.84% |
| 2009 Q1 | 11.38 Billion USD | 19.3% |
| 2009 Q2 | 11.14 Billion USD | -2.07% |
| 2009 Q3 | 10.95 Billion USD | -1.7% |
| 2008 Q2 | 8.68 Billion USD | -3.34% |
| 2008 FY | 9.54 Billion USD | 16.22% |
| 2008 Q1 | 8.98 Billion USD | 9.46% |
| 2008 Q3 | 9.05 Billion USD | 4.23% |
| 2008 Q4 | 9.54 Billion USD | 5.39% |
| 2007 Q1 | 7.87 Billion USD | 12.2% |
| 2007 Q2 | 7.1 Billion USD | -9.77% |
| 2007 Q3 | 7.04 Billion USD | -0.84% |
| 2007 Q4 | 8.2 Billion USD | 16.56% |
| 2007 FY | 8.2 Billion USD | 17.02% |
| 2006 Q1 | 6.29 Billion USD | 10.09% |
| 2006 Q3 | 6.65 Billion USD | 7.54% |
| 2006 Q4 | 7.01 Billion USD | 5.46% |
| 2006 FY | 7.01 Billion USD | 22.66% |
| 2006 Q2 | 6.18 Billion USD | -1.75% |
| 2005 Q4 | 5.71 Billion USD | 1.67% |
| 2005 FY | 5.71 Billion USD | 11.83% |
| 2005 Q3 | 5.62 Billion USD | 2.11% |
| 2005 Q2 | 5.5 Billion USD | -3.89% |
| 2005 Q1 | 5.73 Billion USD | 12.07% |
| 2004 Q1 | 4.72 Billion USD | 12.16% |
| 2004 Q2 | 4.55 Billion USD | -3.51% |
| 2004 Q3 | 4.74 Billion USD | 4.23% |
| 2004 FY | 5.11 Billion USD | 21.47% |
| 2004 Q4 | 5.11 Billion USD | 7.69% |
| 2003 Q3 | 3.98 Billion USD | -0.95% |
| 2003 Q2 | 4.02 Billion USD | 1.51% |
| 2003 FY | 4.21 Billion USD | 15.39% |
| 2003 Q1 | 3.96 Billion USD | 8.75% |
| 2003 Q4 | 4.21 Billion USD | 5.53% |
| 2002 FY | 3.64 Billion USD | 0.61% |
| 2002 Q3 | 3.44 Billion USD | 0.85% |
| 2002 Q4 | 3.64 Billion USD | 5.81% |
| 2002 Q1 | 4.26 Billion USD | 17.66% |
| 2002 Q2 | 3.41 Billion USD | -19.87% |
| 2001 Q4 | 3.62 Billion USD | 5.38% |
| 2001 Q3 | 3.44 Billion USD | 1.87% |
| 2001 Q2 | 3.37 Billion USD | -2.83% |
| 2001 FY | 3.62 Billion USD | 26.38% |
| 2001 Q1 | 3.47 Billion USD | 21.15% |
| 2000 Q1 | 2.87 Billion USD | 18.53% |
| 2000 Q2 | 2.57 Billion USD | -10.17% |
| 2000 Q3 | 2.6 Billion USD | 0.9% |
| 2000 FY | 2.86 Billion USD | 18.47% |
| 2000 Q4 | 2.86 Billion USD | 10.28% |
| 1999 Q4 | 2.42 Billion USD | 7.47% |
| 1999 Q1 | 2.29 Billion USD | 11.93% |
| 1999 FY | 2.42 Billion USD | 17.99% |
| 1999 Q2 | 2.26 Billion USD | -1.25% |
| 1999 Q3 | 2.25 Billion USD | -0.67% |
| 1998 FY | 2.05 Billion USD | 11.94% |
| 1998 Q1 | 2.02 Billion USD | 10.47% |
| 1998 Q2 | 1.91 Billion USD | -5.73% |
| 1998 Q3 | 1.87 Billion USD | -1.68% |
| 1998 Q4 | 2.05 Billion USD | 9.32% |
| 1997 Q1 | 1.86 Billion USD | 17.4% |
| 1997 Q2 | 1.71 Billion USD | -8.24% |
| 1997 Q3 | 1.72 Billion USD | 0.55% |
| 1997 Q4 | 1.83 Billion USD | 6.45% |
| 1997 FY | 1.83 Billion USD | 15.31% |
| 1996 Q4 | 1.59 Billion USD | 4.78% |
| 1996 Q2 | 1.61 Billion USD | -4.22% |
| 1996 Q1 | 1.68 Billion USD | 15.28% |
| 1996 FY | 1.59 Billion USD | 8.94% |
| 1996 Q3 | 1.51 Billion USD | -5.84% |
| 1995 Q1 | 1.5 Billion USD | 12.4% |
| 1995 Q3 | 1.41 Billion USD | 5.33% |
| 1995 Q2 | 1.34 Billion USD | -10.54% |
| 1995 Q4 | 1.46 Billion USD | 3.25% |
| 1995 FY | 1.46 Billion USD | 9.36% |
| 1994 Q2 | 1.2 Billion USD | -5.25% |
| 1994 Q4 | 1.33 Billion USD | 5.83% |
| 1994 Q3 | 1.26 Billion USD | 4.72% |
| 1994 FY | 1.33 Billion USD | 15.45% |
| 1994 Q1 | 1.27 Billion USD | 9.95% |
| 1993 Q1 | 1.26 Billion USD | 11.2% |
| 1993 Q4 | 1.15 Billion USD | 3.25% |
| 1993 Q3 | 1.12 Billion USD | 3.93% |
| 1993 FY | 1.15 Billion USD | 1.41% |
| 1993 Q2 | 1.07 Billion USD | -15.01% |
| 1992 FY | 1.14 Billion USD | 12.52% |
| 1992 Q1 | 1.1 Billion USD | 8.55% |
| 1992 Q2 | 1.08 Billion USD | -1.77% |
| 1992 Q3 | 1.08 Billion USD | 0.42% |
| 1992 Q4 | 1.14 Billion USD | 5.1% |
| 1991 Q3 | 1.01 Billion USD | 1.27% |
| 1991 Q1 | 1.05 Billion USD | 9.44% |
| 1991 FY | 1.01 Billion USD | 4.87% |
| 1991 Q2 | 1 Billion USD | -5.39% |
| 1991 Q4 | 1.01 Billion USD | 0.02% |
| 1990 Q4 | 966.3 Million USD | 6.2% |
| 1990 FY | 966.3 Million USD | 12.66% |
| 1990 Q3 | 909.9 Million USD | 0.71% |
| 1990 Q2 | 903.5 Million USD | -7.05% |
| 1990 Q1 | 972 Million USD | 13.33% |
| 1989 FY | 857.7 Million USD | 7.31% |
| 1989 Q4 | 857.7 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| uniQure N.V. | 624.01 Million USD | -10934.44% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -54505.508% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -11047.212% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -25909.783% |
| bluebird bio, Inc. | 424.62 Million USD | -16115.993% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -100042.527% |
| Imunon, Inc. | 8.53 Million USD | -807092.887% |
| Editas Medicine, Inc. | 150.05 Million USD | -45787.535% |
| IQVIA Holdings Inc. | 20.56 Billion USD | -234.761% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | -1864.26% |
| Myriad Genetics, Inc. | 312.9 Million USD | -21906.072% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -6654.66% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -14025.643% |
| Verastem, Inc. | 71.18 Million USD | -96629.648% |
| Waters Corporation | 3.47 Billion USD | -1880.634% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | -32.713% |
| Biogen Inc. | 12.04 Billion USD | -471.646% |
| Nektar Therapeutics | 267.04 Million USD | -25684.696% |
| Perrigo Company plc | 6.04 Billion USD | -1039.79% |
| Dynavax Technologies Corporation | 375.02 Million USD | -18260.692% |
| Illumina, Inc. | 4.36 Billion USD | -1477.119% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -195643.739% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -35078.146% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -26747.032% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -184542.819% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | -3543.123% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -83430.867% |
| Evolus, Inc. | 209.68 Million USD | -32737.992% |
| Adicet Bio, Inc. | 37.12 Million USD | -185398.384% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -171075.359% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | -868.848% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -10320.406% |
| FibroGen, Inc. | 585.72 Million USD | -11655.798% |
| Agilent Technologies, Inc. | 4.91 Billion USD | -1300.102% |
| OPKO Health, Inc. | 622.47 Million USD | -10961.739% |
| Homology Medicines, Inc. | 118.53 Million USD | -57990.996% |
| Geron Corporation | 146.12 Million USD | -47021.34% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | -1599.953% |
| Exelixis, Inc. | 678.44 Million USD | -10049.238% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -342967.112% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -549261.736% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -27354.068% |
| Zoetis Inc. | 9.29 Billion USD | -640.796% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -17233.025% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -139921.555% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | -1237.081% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -142034.379% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | -2544.902% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | -2762.792% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -59873.696% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | -4074.513% |
| Blueprint Medicines Corporation | 918.64 Million USD | -7395.529% |
| Insmed Incorporated | 1.66 Billion USD | -4043.619% |
| TG Therapeutics, Inc. | 169.08 Million USD | -40623.305% |
| Incyte Corporation | 1.59 Billion USD | -4224.455% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -5707.777% |